Webinar / Dec 15, 2026 · 11:00 AM MST

Peptides III: Peptide Pairings Under the Microscope

Map the rationale behind peptide pairings, proposed pathways of application, and research limitations to help inform thoughtful, evidence-aware conversations with your patients.

Register Now

Why are certain peptides commonly paired, and what does the research support? In the third installment of our peptide education series, we’ll examine BPC-157 paired with TB-500 and BPC-157 paired withKPV, including the rationale behind each pairing and the proposed pathways related to tissue recovery and gastrointestinal health.

This Strive Sessions webinar will distinguish preclinical findings from established human evidence while reviewing risk considerations and the basis and limitations of commonly referenced dosing approaches. Gain a clearer framework for evaluating peptide pairings and discussing research gaps, potential risks, and unanswered questions with patients.


This webinar is designed for:

  • Functional and integrative medicine providers evaluating emerging peptide research and its clinical relevance
  • Sports medicine and musculoskeletal health clinicians interested in proposed tissue recovery pathways
  • Providers focused on gastrointestinal health and intestinal barrier research
  • Prescribing clinicians seeking clearer guidance on evidence limitations, risk considerations, and patient conversations

You’ll learn how to:

  • Explain the rationale for pairing BPC-157 with TB-500 in injectable forms and BPC-157 with KPV in oral forms, including proposed complementary pathways
  • Evaluate findings related to tissue recovery, healthy inflammatory signaling, and gut barrier integrity while recognizing the limits of preclinical evidence
  • Identify key safety considerations, including evidence gaps, patient-specific cautions, and implications for competitive athletes
  • Assess the basis and limitations of commonly referenced dosing approaches and communicate uncertainty clearly during patient discussions

    Disclaimer: Compounded medications are specially prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Individual outcomes may vary. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.

This is intended for informational purposes only and does not constitute medical advice. Strive does not compound peptides for patient use without FDA regulatory authorization or enforcement discretion to do so. Any concentrations and dosing listed reflect Strive's development efforts and development work is ongoing. Peptide compounding is entirely contingent on the FDA's regulatory posture and formal guidance. Strive will follow the FDA's lead.


Content is for educational purposes and does not constitute medical or legal advice. Clinical decisions remain the responsibility of the prescriber.

Compounded medications are specially prepared for individual patient needs based on a valid prescription and, as such, are not reviewed or approved by the FDA. Statements have not been evaluated by the FDA. Availability and permissible compounding practices vary by state law.